Article | 2026 Clinical Trials at the Summit
In RVO, Aflibercept 8 mg Outcomes Unaffected by Baseline CRT
A post hoc analysis of QUASAR data, presented at Clinical Trials at the Summit, finds consistent visual and anatomic results across retinal vein occlusion subtypes.







